



Study Title:	Treatment Trial for Stage III-IV Hodgkin Lymphoma
Scientific Title:	SWOG S0816 - Phase II Study of Response-Adapted Therapy Using Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy Comprising ABVD With Versus Without Combination Chemotherapy Comprising Standard or Escalated BEACOPP in Patients with Stage III-IV Hodgkin Lymphoma
Department and/or Specialty:	Oncology - Hematology - Lymphoma
Investigator:	Michael Thompson, MD, PhD
Contact Information:	Chanda Miller
Purpose: <p><u>Drugs</u> used in <u>chemotherapy</u> work in different ways to stop the growth of <u>cancer cells</u>, either by killing the cells or by stopping them from dividing. Giving more than one drug (<u>combination chemotherapy</u>) may kill more cancer cells. <u>G-CSF</u> may help lessen the <u>side effects</u> in patients receiving chemotherapy. <u>Imaging procedures</u>, such as <u>fludeoxyglucose F 18 - PET /CT</u> imaging, may help doctors predict how patients will respond to treatment.</p> <p>This <u>phase II trial</u> is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing response to combination chemotherapy and allow doctors to plan better additional further treatment in treating patients with <u>stage III</u> or <u>stage IV Hodgkin lymphoma</u>.</p>	



PROHEALTH CARE
RESEARCH INSTITUTE